Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04740918 2025-08-08

KATE3

Phase 3 Terminated

96 enrolled 16 charts

Breast

Breast Neoplasms

NCT04690855 2023-12-04

TARA

Phase 2 Terminated

1 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02322814 2023-04-13

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Phase 2 Terminated

169 enrolled 31 charts

Breast

Breast Neoplasms

NCT04102618 2022-08-15

AWARE-1

Phase EARLY_PHASE1 Terminated

26 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03147040 2022-07-19

GELATO

Phase 2 Terminated

23 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03894007 2021-09-23

PREDIXIIHER2

Phase 2 Terminated

6 enrolled

Breast

Breast Neoplasms

NCT03566485 2021-08-11

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Breast

Breast Neoplasms

NCT03952325 2021-07-30

CONTESSA TRIO

Phase 2 Terminated

294 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Clinical Trials

BIS-Program

KATE3

TARA

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

AWARE-1

GELATO

PREDIXIIHER2

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

CONTESSA TRIO